These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 34093445)

  • 1. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy.
    Hu Y; Ye Z; Wang F; Qin Y; Xu X; Yu X; Ji S
    Front Endocrinol (Lausanne); 2021; 12():679000. PubMed ID: 34093445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
    Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
    Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).
    Kolasińska-Ćwikła AD; Konsek SJ; Buscombe JR; Maciejkiewicz K; Cichocki A; Roszkowska-Purska K; Sawicki Ł; Tenderenda M; Cwikla JB
    Nucl Med Rev Cent East Eur; 2019; 22(1):1-7. PubMed ID: 30276787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioguided surgery with radiolabeled somatostatin analogs: not only in GEP-NETs.
    Cuccurullo V; Di Stasio GD; Mansi L
    Nucl Med Rev Cent East Eur; 2017; 20(1):49-56. PubMed ID: 28218348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
    Hofsli E
    Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
    Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
    Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
    Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
    J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
    Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
    Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor imaging and therapy using radiolabeled somatostatin analogues.
    de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
    Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
    Pusceddu S; De Braud F; Festinese F; Bregant C; Lorenzoni A; Maccauro M; Milione M; Concas L; Formisano B; Leuzzi L; Mazzaferro V; Buzzoni R
    Future Oncol; 2015; 11(13):1947-59. PubMed ID: 26161929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of somatostatin receptor-2 positivitiy in gastroenteropancreatic neuroendocrine tumors in reference to known prognostic factors.
    Yenıay L; Gürcü B; Ünalp Ö; Yilmaz F; Nart D; Sözbılen M; Çoker A
    Turk J Gastroenterol; 2012; 23(6):736-40. PubMed ID: 23794313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.
    Konukiewitz B; Schlitter AM; Jesinghaus M; Pfister D; Steiger K; Segler A; Agaimy A; Sipos B; Zamboni G; Weichert W; Esposito I; Pfarr N; Klöppel G
    Mod Pathol; 2017 Apr; 30(4):587-598. PubMed ID: 28059098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
    Janson ET
    J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
    Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
    Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters.
    Faggiano A; Modica R; Lo Calzo F; Camera L; Napolitano V; Altieri B; de Cicco F; Bottiglieri F; Sesti F; Badalamenti G; Isidori AM; Colao A
    J Clin Endocrinol Metab; 2020 Jan; 105(1):. PubMed ID: 31586182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
    Hankus J; Tomaszewska R
    Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Masking effect of chronic pancreatitis in the interpretation of somatostatin receptor positron emission tomography in pancreatic neuroendocrine tumors.
    Treglia G; Farchione A; Stefanelli A; Brizi MG; Larghi A; Inzani F; Rindi G; Rufini V
    Pancreas; 2013 May; 42(4):726-8. PubMed ID: 23591437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.